Peer-reviewed veterinary case report
Stem cell injection to treat osteoarthritis in dogs
By Srzentić Dražilov, Sanja et al.·Published in Acta veterinaria Hungarica·2018·Institute of Molecular Genetics and Genetic Engineering·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The use of canine mesenchymal stem cells for the autologous treatment of osteoarthritis.
- Species:
- dog
Plain-English summary
Ten dogs with osteoarthritis (OA) received a single injection of their own fat-derived stem cells to help relieve their joint pain and improve mobility. After treatment, the dogs showed significant improvement in their ability to move and function over the next three months. For five of these dogs, follow-up evaluations over one to four years revealed that some benefits lasted long-term. This suggests that using stem cells from a dog's own body can be an effective treatment for osteoarthritis, potentially reducing the need for surgery or other invasive procedures.
People also search for: dog osteoarthritis treatment · stem cell therapy for dogs · how to help my dog with joint pain
Abstract
Mesenchymal stem cells (MSCs) hold enormous potential for cell-based therapy in the treatment of various diseases, particularly those which currently cannot be cured and result in poor outcomes or invasive surgery. Here we present results of the application of autologous, culture-expanded, adipose tissue (AT)-derived MSCs for the osteoarthritis (OA) treatment of 10 canine patients. The stemness of isolated cells has been confirmed by their ability to differentiate into osteo- and chondrocytic lineages. The clinical effect of a single injection of ATMSCs into the symptomatic joints was evaluated by a veterinarian for five disabilities characteristic of OA at 30, 60 and 90 days after treatment, which has been designated as the initial evaluation period. Functional outcomes for all analysed characteristics improved significantly at the end of this evaluation compared with the baseline. In addition, for 5 of these 10 patients, an extended follow-up study was performed from 1 to 4 years after the initial evaluation period. We detected long-lasting positive effects on two out of five analysed characteristics. The results demonstrate that the use of autologous AT-MSCs is a successful approach to canine OA therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30264620/